妇科癌症
乳腺癌
抗体-药物偶联物
药品
抗体
医学
结合
癌症
肿瘤科
妇科
内科学
卵巢癌
免疫学
药理学
单克隆抗体
数学
数学分析
作者
Ayumi Saito,Kan Yonemori
出处
期刊:PubMed
日期:2024-07-01
卷期号:51 (7): 695-701
摘要
Antibody-drug conjugates(ADCs)have become widely used in the treatment of various malignancies over the past 15 years. In breast cancer, T-DM1 and T-DXd which is HER2-targeted ADC have been approved and are broadly used in Japan. Sacituzumab govitecan, TROP2-ADC has been approved in US. Hence, multiple ADCs could be used for breast cancer treatment. In gynecological cancers, tisotumab vedotin for cervical cancer and mirvetuximab soravtansine for ovarian cancer have been approved in the US. Optimizing treatment sequences and overcoming resistance mechanisms for ADC are important challenges in the situations where multiple ADCs are available. The current development landscape suggests further enhancement of ADC treatment efficacy through new targets, novel payloads, bispecific ADCs, and combination therapies with immunotherapy. This article outlines the current status of ADCs in breast and gynecological cancers, highlighting ongoing development and challenges emerging in the field.
科研通智能强力驱动
Strongly Powered by AbleSci AI